CA2943871C - POXVIRAL ONCOLYTIC VECTORS - Google Patents

POXVIRAL ONCOLYTIC VECTORS

Info

Publication number
CA2943871C
CA2943871C CA2943871A CA2943871A CA2943871C CA 2943871 C CA2943871 C CA 2943871C CA 2943871 A CA2943871 A CA 2943871A CA 2943871 A CA2943871 A CA 2943871A CA 2943871 C CA2943871 C CA 2943871C
Authority
CA
Canada
Prior art keywords
composition
cancer
treatment
administration
poxvirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2943871A
Other languages
English (en)
French (fr)
Other versions
CA2943871A1 (en
Inventor
Philippe Erbs
Johann Foloppe
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/249,713 external-priority patent/US9687515B2/en
Application filed by Transgene SA filed Critical Transgene SA
Publication of CA2943871A1 publication Critical patent/CA2943871A1/en
Application granted granted Critical
Publication of CA2943871C publication Critical patent/CA2943871C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2943871A 2014-04-10 2015-04-09 POXVIRAL ONCOLYTIC VECTORS Active CA2943871C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/249,713 US9687515B2 (en) 2007-11-19 2014-04-10 Poxviral oncolytic vectors
US14/249,713 2014-04-10
PCT/EP2015/057654 WO2015155263A1 (en) 2014-04-10 2015-04-09 Poxviral oncolytic vectors

Publications (2)

Publication Number Publication Date
CA2943871A1 CA2943871A1 (en) 2015-10-15
CA2943871C true CA2943871C (en) 2025-05-06

Family

ID=53051793

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2943871A Active CA2943871C (en) 2014-04-10 2015-04-09 POXVIRAL ONCOLYTIC VECTORS

Country Status (10)

Country Link
EP (1) EP3129037B1 (enExample)
JP (1) JP6657115B2 (enExample)
KR (1) KR102457060B1 (enExample)
CN (1) CN106413726B (enExample)
AU (1) AU2015243297B2 (enExample)
CA (1) CA2943871C (enExample)
DK (1) DK3129037T3 (enExample)
ES (1) ES2768715T3 (enExample)
IL (1) IL247535B (enExample)
WO (1) WO2015155263A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018091680A1 (en) * 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
WO2018182014A1 (ja) * 2017-03-31 2018-10-04 久修 緒方 腫瘍溶解性ウイルスの増殖方法及び抗腫瘍剤
CA3124773A1 (en) * 2018-12-28 2020-07-02 Transgene M2-defective poxvirus
CN110747174A (zh) * 2019-10-30 2020-02-04 青岛宁逸生物科技有限公司 一种用于肿瘤治疗的重组病毒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
EP0575491B1 (en) * 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5856153A (en) 1994-11-17 1999-01-05 Cayla Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases
FR2777570A1 (fr) 1998-04-17 1999-10-22 Transgene Sa Mutant ayant une activite phosphoribosyl transferase
AU5446700A (en) 1999-05-28 2000-12-18 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
WO2004014314A2 (en) 2002-08-12 2004-02-19 David Kirn Methods and compositions concerning poxviruses and cancer
DK1649023T3 (da) 2003-07-21 2008-10-06 Transgene Sa Polypeptid med forbedret cytosindeaminaseaktivitet
ES2320157T3 (es) 2004-11-08 2009-05-19 Transgene S.A. Kit de partes diseñado para poner en practica un tratamiento atitumoral o antivirico en un mamifero.
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
JP2010533718A (ja) * 2007-07-18 2010-10-28 ジェネラックス・コーポレイション 腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用
DK2212345T3 (en) 2007-11-19 2016-03-21 Transgene Sa Oncolytic poxvirus vectors
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
CA2709292A1 (en) 2009-07-10 2011-01-10 The Governors Of The University Of Alberta Oncolytic viruses and methods for treating neoplastic disorders

Also Published As

Publication number Publication date
EP3129037A1 (en) 2017-02-15
WO2015155263A1 (en) 2015-10-15
EP3129037B1 (en) 2019-11-13
CA2943871A1 (en) 2015-10-15
KR20160145058A (ko) 2016-12-19
IL247535B (en) 2019-05-30
ES2768715T3 (es) 2020-06-23
DK3129037T3 (da) 2020-02-03
AU2015243297A1 (en) 2016-09-29
AU2015243297A2 (en) 2016-09-29
JP2017515806A (ja) 2017-06-15
CN106413726B (zh) 2020-07-24
KR102457060B1 (ko) 2022-10-19
CN106413726A (zh) 2017-02-15
AU2015243297B2 (en) 2020-10-15
JP6657115B2 (ja) 2020-03-04
IL247535A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
CA2705869C (en) Poxviral oncolytic vectors
CA2705873C (en) Poxviral oncolytic vectors
EP3129037B1 (en) Poxviral oncolytic vectors
US9687515B2 (en) Poxviral oncolytic vectors
HK1230971A1 (en) Poxviral oncolytic vectors
HK1230971B (en) Poxviral oncolytic vectors
HK1141541B (en) Poxviral oncolytic vectors
HK1141314B (en) Poxviral oncolytic vectors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200408

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20250327

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250331

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250331

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250502

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20250505

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20250506

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260521